Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

J. Fox, Robert; H. Miller, David; Theodore Phillips, J.; Hutchinson, Michael; Havrdová, Eva; Kita, Mariko; Yang, Minhua; Raghupathi, Kartik; Novas, Mark; T. Sweetser, Marianne; Viglietta, Vissia; Dawson, Katherine

doi:10.1056/nejmoa1206328

Public

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Published in New England Journal of Medicine • Sep 19, 2012

Authors:

Robert J. Fox

David H. Miller

J. Theodore Phillips

Abstract

BACKGROUND: BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate). METHODS: In this phase 3, randomized study, we investigated the efficacy and safety of oral BG...

Subject

Medicine

Multiple sclerosis

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!